Altimmune Inc (OQ:ALT)

Apr 01, 2024 09:31 am ET
Thinking about buying stock in Ocugen, Ceragon Networks, Gannett, Altimmune, or Nio?
NEW YORK, April 1, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCGN, CRNT, GCI, ALT, and NIO.
Mar 27, 2024 07:00 am ET
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. “We are extremely pleased with the...
Mar 20, 2024 07:30 am ET
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024 and will provide a business update. Altimmune...
Mar 07, 2024 04:36 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT
Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.   The...
Feb 28, 2024 03:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT
Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
Feb 28, 2024 02:18 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune, Inc. (NASDAQ: ALT) resulting from allegations that Altimmune may have issued materially...
Feb 26, 2024 08:31 am ET
Thinking about buying stock in Intuitive Machines, SoundHound AI, Interactive Strength, Altimmune, or NanoVibronix?
NEW YORK, Feb. 26, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LUNR, SOUN, TRNR, ALT, and NAOV.
Feb 26, 2024 04:00 am ET
Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Altimmune, Inc. (“Altimmune” or “the Company”) (NASDAQ: ALT). Investors who purchased Altimmune securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ALT.
Feb 24, 2024 01:15 pm ET
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Altimmune, Inc. (NASDAQ: ALT) resulting from allegations that Altimmune may have issued materially...
Feb 24, 2024 09:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT
NEW YORK, Feb. 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  
Feb 20, 2024 03:37 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT
Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.   The...
Feb 19, 2024 04:53 pm ET
NATIONALLY RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune, Inc. (NASDAQ: ALT) resulting from allegations that Altimmune may have issued materially...
Feb 15, 2024 04:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT
NEW YORK, Feb. 15, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Feb 14, 2024 04:39 pm ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Altimmune, Inc. (NASDAQ: ALT) resulting from allegations that Altimmune may have issued materially misleading business information to the investing public.
Feb 12, 2024 08:31 am ET
Thinking about trading options or stock in Amazon, Eli Lilly, Altimmune, Novavax, or Snap?
NEW YORK, Feb. 12, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMZN, LLY, ALT, NVAX, and SNAP.
Jan 05, 2024 08:31 am ET
Thinking about buying stock in C3.ai, Altimmune, Altria Group, Fusion Pharmaceuticals, or Aurinia Pharmaceuticals?
NEW YORK, Jan. 5, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AI, ALT, MO, FUSN, and AUPH.
Jan 04, 2024 08:31 am ET
Thinking about buying stock in Minim, Aurora Innovation, Altimmune, SNDL Inc, or Tigo Energy?
NEW YORK, Jan. 4, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MINM, AUR, ALT, SNDL, and TYGO.
Jan 02, 2024 07:30 am ET
Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an abstract on pemvidutide in subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease1 will be presented at the NASH-TAG Conference, which...
Dec 18, 2023 08:31 am ET
Thinking about buying stock in Finch Therapeutics, Palantir Technologies, Altimmune, Dorian LPG, or Cuentas?
NEW YORK, Dec. 18, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FNCH, PLTR, ALT, LPG, and CUEN.
Dec 01, 2023 08:31 am ET
Thinking about buying stock in Altimmune, UiPath, Incannex Healthcare, Cartesian Therapeutics, or Rivian Automotive?
NEW YORK, Dec. 1, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALT, PATH, IXHL, RNAC, and RIVN.
Nov 30, 2023 04:24 pm ET
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the “Company”), today announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide. The trial enrolled 391 subjects with obesity or overweight...
Nov 07, 2023 07:00 am ET
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended September 30, 2023, and provided a business update. “The next few months will be important as we receive the...
Oct 31, 2023 07:30 am ET
Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023 and will provide a business update. Altimmune management will...
Oct 26, 2023 07:30 am ET
Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its clinical program investigating pemvidutide for the treatment of...
Oct 25, 2023 07:30 am ET
Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide from its 24-week Phase 1b randomized, placebo-controlled study in subjects...
Oct 17, 2023 07:30 am ET
Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: H.C. Wainwright...
Sep 26, 2023 07:30 am ET
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Louis J. Aronne, Founder and Director of the Center for Weight Management at Weill-Cornell Medical Center, and a leading authority in obesity, will...
Sep 12, 2023 07:30 am ET
Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the completion of dosing (last subject last dose) in its 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of pemvidutide in subjects with...
Aug 30, 2023 07:30 am ET
Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Wells Fargo 2023...
Aug 10, 2023 07:00 am ET
Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended June 30, 2023, and provided a business update. “We are pleased to have commenced enrollment in our IMPACT Phase...
Aug 03, 2023 07:30 am ET
Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2023 financial results on Thursday, August 10, 2023 and will provide a business update. Altimmune management will...
Aug 01, 2023 07:30 am ET
Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the Phase 2b IMPACT trial evaluating the efficacy and safety of pemvidutide in subjects with non-alcoholic...
Jun 16, 2023 07:30 am ET
Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, has been invited to participate on a Metabolic panel at the Healthcare Virtual Conference Part II,...
Jun 15, 2023 07:30 am ET
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research and Adjunct Professor of Medicine, Oxford University, will present the results of...
May 31, 2023 07:30 am ET
Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Jefferies...
May 11, 2023 07:00 am ET
Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended March 31, 2023, and provided a business update. “We are on course for mid-year initiation of IMPACT, our Phase...
May 08, 2023 07:30 am ET
Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: JMP Securities Life...
May 04, 2023 07:30 am ET
Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2023 financial results on Thursday, May 11, 2023 and will provide a business update. Altimmune management will host a...
Apr 18, 2023 09:31 am ET
Thinking about buying stock in Advanced Micro Devices, BigBear.ai, Riot Platforms, Bit Digital, or Altimmune?
NEW YORK, April 18, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, BBAI, RIOT, BTBT, and ALT.
Apr 17, 2023 09:58 am ET
Thinking about buying stock in AMC Entertainment, Li Auto, Kingsoft Cloud, Altimmune, or Ford Motor?
NEW YORK, April 17, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, LI, KC, ALT, and F.
Apr 11, 2023 07:30 am ET
Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis B
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the Company), today announced that it has completed enrollment in its Phase 2 clinical trial of HepTcell, an immunotherapeutic for the treatment of chronic hepatitis B...
Mar 27, 2023 04:05 pm ET
Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors. “We are delighted to welcome Catherine to our Board of Directors,” said Vipin...
Mar 21, 2023 07:00 am ET
Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the “Company”), today announced topline results from a Week 24 interim analysis of 160 subjects in its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide along with the...
Feb 28, 2023 07:00 am ET
Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update. “The next twelve-months is an important...
Feb 21, 2023 07:30 am ET
Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023 and will provide a business update. Altimmune...
Jan 04, 2023 07:30 am ET
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder, Pinnacle Clinical Research and Summit Clinical Research, will deliver an oral presentation of the...
Jan 04, 2023 07:30 am ET
Altimmune Appoints Raymond Jordt as Chief Business Officer
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023. Mr. Jordt succeeds José Ochoa, who is leaving Altimmune to pursue...
Dec 20, 2022 07:00 am ET
Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced topline results from its 24-week (12-week extension) trial of pemvidutide in subjects with NAFLD. Sixty-six (66) of the 83 subjects who completed the...
Dec 01, 2022 07:35 am ET
Thinking about buying stock in Altimmune, Lordstown Motors, Sonim Technologies, Nutanix, or RA Medical?
NEW YORK, Dec. 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALT, RIDE, SONM, NTNX, and RMED.
Nov 22, 2022 07:30 am ET
Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences: Evercore ISI 5th Annual HealthCONx Virtual...
Nov 10, 2022 07:00 am ET
Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2022, and provided a business update. “We continue on course in our advancement of...
Nov 03, 2022 07:30 am ET
Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2022 financial results on Thursday, November 10, 2022 and will provide a business update. Altimmune management will...
Oct 28, 2022 07:30 am ET
Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting®
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022: American Heart Association Scientific Sessions 2022, Chicago,...
Oct 14, 2022 08:58 am ET
Thinking about buying stock in Imara, Nutanix, Azul, 22nd Century Group, or Altimmune?
NEW YORK, Oct. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMRA, NTNX, AZUL, XXII, and ALT.
Sep 28, 2022 07:30 am ET
Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the completion of first dosing of all subjects in its Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide1 in subjects with obesity or...
Sep 14, 2022 10:46 am ET
Thinking about buying stock in Altimmune, Transocean, Cleveland-Cliffs, Ensysce Biosciences, or Kiora Pharmaceuticals?
NEW YORK, Sept. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALT, RIG, CLF, ENSC, and KPRX.
Sep 14, 2022 07:00 am ET
Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive topline results from its 12-week Phase 1b study of pemvidutide1 in subjects with non-alcoholic fatty liver disease (NAFLD). The trial was a...
Aug 11, 2022 07:00 am ET
Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2022, and provided a business update. “We continue to advance the development of...
Aug 04, 2022 07:30 am ET
Altimmune to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2022 financial results on Thursday, August 11, 2022 and will provide a business update. Altimmune management will...
Jun 17, 2022 07:30 am ET
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research, will present the results of Altimmune’s recently completed Phase 1,...
Jun 03, 2022 07:30 am ET
Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in June 2022: Jefferies 2022 Global Healthcare...
May 31, 2022 07:30 am ET
Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Samuel Klein, William H. Danforth Professor of Medicine and Nutritional Science Director, Washington University School of Medicine, will deliver an...
May 20, 2022 07:30 am ET
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5th Global NASH Congress on May 26-27, 2022, in London, UK....
May 16, 2022 07:30 am ET
Altimmune to Present at Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in May 2022: H.C. Wainwright Global Investment...
May 12, 2022 07:00 am ET
Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended March 31, 2022 and provided a corporate update. “We continue to advance the development of pemvidutide, our...
May 05, 2022 07:30 am ET
Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2022 financial results on Thursday, May 12, 2022 and will provide a business update. Altimmune management will host a...
Apr 01, 2022 07:00 am ET
Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the 48-week Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide1 in subjects with obesity or...
Mar 15, 2022 07:01 am ET
Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. “We expect the next 12 months to...
Mar 08, 2022 07:00 am ET
Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022. Altimmune management will host a conference call at...
Jan 31, 2022 07:35 am ET
Thinking about buying stock in Viking Therapeutics, KemPharm, Bluejay Diagnostics, Altimmune, or DocGo?
NEW YORK, Jan. 31, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VKTX, KMPH, BJDX, ALT, and DCGO.
Jan 31, 2022 07:00 am ET
Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for its Phase 2 clinical trial of...
Jan 03, 2022 07:00 am ET
Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral and a poster presentation on pemvidutide, the Company’s novel, investigational...
Dec 13, 2021 06:00 am ET
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of Directors granted equity awards under Altimmune’s 2018 Inducement Grant Plan, as a material inducement to...
Dec 13, 2021 06:00 am ET
Altimmune Appoints Richard Eisenstadt as Chief Financial Officer
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases, today announced the appointment of Richard Eisenstadt as Chief Financial Officer, effective December 31,...
Nov 22, 2021 04:01 pm ET
Altimmune to Present at Upcoming Investor and Scientific Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting virtually at the following conferences: Piper Sandler 33rd Annual Virtual Healthcare...
Nov 10, 2021 04:01 pm ET
Altimmune to Present at Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting virtually at the following investor conferences in November 2021: Stifel’s 2021 Virtual...
Nov 09, 2021 04:01 pm ET
Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three- and nine-months ending September 30, 2021 and provided a corporate update. “The third quarter was a momentous time...
Nov 03, 2021 04:01 pm ET
Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial results on Wednesday, November 10, 2021. Altimmune management will host a conference call for investors...
Oct 15, 2021 09:35 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Oct 11, 2021 03:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980. The...
Oct 06, 2021 04:01 pm ET
Altimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will be presenting virtually at the following H.C. Wainwright Investor Conferences: H.C. Wainwright 5th Annual NASH...
Oct 04, 2021 07:00 am ET
Altimmune Announces Initiation of 12-week Phase 1b Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in a Phase 1b clinical trial of pemvidutide (proposed INN, formerly known as ALT-801) in subjects with non-alcoholic...
Oct 03, 2021 08:52 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980. The...
Sep 29, 2021 06:15 pm ET
Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on its 12-week Phase 1 clinical trial of pemvidutide (proposed INN, formerly known as ALT-801) in...
Sep 28, 2021 10:40 am ET
Thinking about buying stock in Farmmi, Naked Brand, Southwestern Energy, Altimmune, or Rewalk Robotics?
NEW YORK, Sept. 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FAMI, NAKD, SWN, ALT, and RWLK.
Sep 28, 2021 07:01 am ET
Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from a 12-week, Phase 1 trial of pemvidutide (proposed INN, formerly known as ALT-801), an investigational glucagon-like peptide-1...
Sep 27, 2021 04:01 pm ET
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week Phase 1 clinical trial of ALT-801 in overweight and obese subjects in a pre-market press release and webcast...
Sep 27, 2021 08:30 am ET
Thinking about buying stock in Vizio, Li-Cycle Holdings, Matinas BioPharma, Frontline, or Altimmune?
NEW YORK, Sept. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VZIO, LICY, MTNB, FRO, and ALT.
Sep 08, 2021 09:31 am ET
Thinking about buying stock in Nabriva Therapeutics, WiMi Hologram Cloud, Xos Inc, Altimmune, or Penn National Gaming?
NEW YORK, Sept. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NBRV, WIMI, XOS, ALT, and PENN.
Sep 07, 2021 04:01 pm ET
Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually...
Aug 10, 2021 04:01 pm ET
Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three- and six-months ending June 30, 2021 and provided a corporate update. “Following data readouts in Q2, Altimmune has focused...
Aug 04, 2021 04:01 pm ET
Altimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 11, 2021. Altimmune management will host a conference call for investors...
Jun 30, 2021 11:15 am ET
Thinking about buying stock in Check Cap, ContextLogic, Marin Software, Atossa Therapeutics, or Altimmune?
NEW YORK, June 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHEK, WISH, MRIN, ATOS, and ALT.
Jun 29, 2021 04:01 pm ET
Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19. The Company also provided an update on its T-COVID Phase 1/2 clinical trial...
Jun 16, 2021 08:32 am ET
Thinking about buying stock in Catabasis Pharmaceuticals, Arrival, MannKind, Trevena, or Altimmune?
NEW YORK, June 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CATB, ARVL, MNKD, TRVN, and ALT.
Jun 16, 2021 07:00 am ET
Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced results from a prespecified 6-week interim analysis of its ongoing 12-week, Phase 1, placebo-controlled, single and multiple ascending dose trial of ALT-801,...
Jun 10, 2021 10:55 am ET
Thinking about buying stock in Clover Health Investments, New Oriental Education, Altimmune, BlackBerry, or Microvision?
NEW YORK, June 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLOV, EDU, ALT, BB, and MVIS.
May 27, 2021 07:00 am ET
Altimmune to Present at the 2021 Jefferies Virtual Healthcare Conference
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the 2021 Jefferies Virtual Healthcare Conference, being held June 1 - 4, 2021....
May 26, 2021 07:00 am ET
Altimmune Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID™
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced new results from a preclinical study demonstrating the ability of its AdCOVID vaccine candidate to neutralize the rapidly emerging SARS-CoV-2 B.1.351 variant...
May 17, 2021 07:00 am ET
Altimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ending March 31, 2021 and provided a corporate update. “With AdCOVID™, our single-dose intranasal vaccine candidate...
May 11, 2021 07:00 am ET
Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2021 financial results on Monday, May 17, 2021. Altimmune management will host a conference call for investors...
May 10, 2021 07:00 am ET
Altimmune Announces New Preclinical Data for AdCOVID™ Demonstrating Sterilizing Immunity After a Single Intranasal Dose
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from a preclinical study of AdCOVID in a SARS-CoV-2 challenge model of infection. In this study, a single intranasal dose of AdCOVID...
Apr 29, 2021 07:00 am ET
Altimmune to Present at Upcoming Scientific Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting at two scientific conferences in May 2021. Scot Roberts, Ph.D., Chief Scientific Officer...
Apr 01, 2021 07:00 am ET
Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate. The Phase 1b trial evaluated the safety and immunogenicity of one and two-dose regimens...
Mar 22, 2021 07:00 am ET
Altimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID™ Vaccine Candidate
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, announced today that it has retained Summit Biosciences, a world-wide leader in nasal spray pharmaceuticals, to manufacture a metered nasal spray presentation of AdCOVID,...
Mar 15, 2021 07:00 am ET
AdCOVID™, Altimmune’s Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced additional preclinical data for its single dose intranasal COVID-19 vaccine candidate, AdCOVID. The preclinical studies were conducted at Altimmune’s...
Mar 12, 2021 01:00 am ET
Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has expanded its previously-announced AdCOVID manufacturing collaboration with Lonza. Under the expanded agreement, Lonza will commission a dedicated...
Mar 08, 2021 04:01 pm ET
Altimmune to Present at Upcoming Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright Global Life Sciences Conference, being held Mar 9-10, 2021....
Feb 25, 2021 07:03 am ET
Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID™ -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has commenced enrollment in a Phase 1 clinical trial of AdCOVID, a single-dose intranasal COVID-19 vaccine candidate. AdCOVID is an adenovirus-vector...
Feb 25, 2021 07:00 am ET
Altimmune Announces Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December 31, 2020 and provided a corporate update. “The past year has been a transformative time for our Company as...
Feb 22, 2021 04:30 pm ET
Altimmune To Announce Year End 2020 Financial Results on February 25, 2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25th, 2021. Altimmune management will host a conference call for investors...
Feb 17, 2021 07:34 am ET
Thinking about buying stock in Comstock Mining, Oncolytics Biotech, Salarius Pharmaceuticals, Altimmune, or Creative Realities?
NEW YORK, Feb. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LODE, ONCY, SLRX, ALT, and CREX.
Feb 17, 2021 07:02 am ET
Altimmune Announces FDA Clearance of AdCOVID™ IND Application
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for its Phase 1 clinical trial of...
Jan 04, 2021 08:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
NEW YORK, Jan. 4, 2021 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" the "Company") (NASDAQ: ALT).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Jan 04, 2021 08:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
NEW YORK, Jan. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" the "Company") (NASDAQ: ALT).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Dec 30, 2020 08:00 am ET
Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in its multinational Phase 2 clinical trial of HepTcell, a novel peptide-based immunotherapeutic under development for...
Dec 23, 2020 04:01 pm ET
Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a clinical hold on the Company’s Investigational New Drug (IND) application for AdCOVID, a...
Dec 11, 2020 07:00 am ET
Altimmune to Present at the 4th Annual NASH Summit 2020 Digital Conference
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer of Altimmune will give an oral presentation on ALT-801, the Company’s novel GLP-1/Glucagon dual receptor agonist...
Dec 08, 2020 08:00 am ET
Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has commenced dosing in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical study of ALT-801. ALT-801 is a long-acting...
Dec 01, 2020 07:30 am ET
Thinking about buying stock in Titan Pharmaceuticals, Moderna, Moleculin Biotech, Corbus Pharmaceuticals, or Altimmune?
NEW YORK, Dec. 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTNP, MRNA, MBRX, CRBP, and ALT.
Nov 25, 2020 08:31 am ET
Thinking about buying stock in Altimmune, General Electric, Moderna, Delta Air Lines, or Norwegian Cruise Line?
NEW YORK, Nov. 25, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALT, GE, MRNA, DAL, and NCLH.
Nov 25, 2020 07:00 am ET
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and...
Nov 16, 2020 07:00 am ET
Altimmune to Present at Upcoming Virtual Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual investor...
Nov 10, 2020 08:31 am ET
Thinking about buying stock in Xperi, Transocean, Fulgent Genetics, Vaxart, or Altimmune?
NEW YORK, Nov. 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XPER, RIG, FLGT, VXRT, and ALT.
Nov 10, 2020 01:00 am ET
Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID™ its Single-Dose Intranasal Vaccine Candidate for COVID-19
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it entered into an agreement with Lonza for the manufacturing of AdCOVID™, Altimmune’s next-generation, single-dose intranasal vaccine candidate for...
Nov 09, 2020 04:05 pm ET
Altimmune Announces Third Quarter 2020 Financial Results and Provides a Business Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2020 and provided a business update. “2020 has been a transformational year for...
Nov 03, 2020 08:00 am ET
Altimmune to Announce Third Quarter 2020 Financial Results on November 10
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial results on Tuesday, November 10, 2020. Altimmune management will host a conference call for investors...
Oct 15, 2020 07:00 am ET
Altimmune to Present at Two Upcoming Virtual Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual investor...
Oct 13, 2020 09:31 am ET
Thinking about buying stock in Altimmune, Dynavax Technologies, GoPro, BioNTech, or Outlook Therapeutics?
NEW YORK, Oct. 13, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALT, DVAX, GPRO, BNTX, and OTLK.
Oct 12, 2020 07:01 am ET
Altimmune and UAB Announce Publication of Compelling Pre-clinical Data for AdCOVID™ Intranasal COVID-19 Vaccine Candidate
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today pre-published a comprehensive preclinical evaluation of its single-dose, intranasal COVID-19 vaccine candidate, AdCOVID, in a manuscript entitled, “Single-dose...
Sep 30, 2020 07:00 am ET
Altimmune to Present at Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following upcoming virtual investor conferences in October: H.C. Wainwright 4th Annual NASH Investor ConferenceMonday,...
Sep 28, 2020 04:01 pm ET
Altimmune Presents Highlights of Intranasal COVID-19 Vaccine and Therapeutic Programs – AdCOVID™ and T-COVID™ – at the World Vaccine Congress
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Scot Roberts, Ph.D., Chief Scientific Officer of Altimmune, Inc., presented an overview of the Company’s AdCOVID and T-COVID intranasal vaccine and...
Sep 01, 2020 07:00 am ET
Altimmune Announces Successful Completion of Multiple Dose Toxicity and Toxicokinetic Studies of ALT-801, a GLP-1/Glucagon Dual Receptor Agonist for the Treatment of NASH
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the successful completion of multiple dose toxicity and toxicokinetic studies of ALT-801, a GLP-1/glucagon dual receptor agonist for the treatment of NASH....
Aug 26, 2020 07:00 am ET
Altimmune Announces Data Presentation on ALT-801, its Balanced and Long-Acting GLP-1/Glucagon Receptor Dual Agonist for NASH, at the Digital International Liver Congress™ 2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced a preclinical data presentation on ALT-801, its balanced and long-acting GLP-1/glucagon receptor dual agonist under development for NASH, at the Digital...
Aug 25, 2020 07:00 am ET
Altimmune and the University of Alabama at Birmingham Announce Potent Respiratory Mucosal T Cell Responses in Preclinical Study of Single-Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID™
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced additional positive results from the preclinical studies of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID. The studies were conducted as...
Aug 11, 2020 04:05 pm ET
Altimmune Announces Second Quarter 2020 Financial Results and Provides a Business Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2020 and provided a business update. “We are pleased with Altimmune’s progress during 2020 as...
Aug 07, 2020 07:00 am ET
Altimmune Completes Enrollment in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment in its Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. With this milestone, the...
Aug 05, 2020 07:00 am ET
Altimmune to Announce Second Quarter 2020 Financial Results on August 12
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the three and six months ended June 30, 2020 and its business outlook before the market open and host a conference...
Jul 31, 2020 09:31 am ET
Thinking about trading options or stock in Altimmune Inc, Apple, Ford Motor, General Electric, or Under Armour?
NEW YORK, July 31, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALT, AAPL, F, GE, and UA.
Jul 22, 2020 07:30 am ET
Altimmune Announces Manufacturing Agreement with Vigene Biosciences for AdCOVID™, its Single Dose Intranasal Vaccine Candidate for COVID-19
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company has entered into an agreement with Vigene Biosciences (“Vigene”) to manufacture AdCOVIDTM, Altimmune’s single-dose intranasal vaccine...
Jul 16, 2020 04:01 pm ET
Altimmune Announces Closing of $132 Million Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that its previously announced underwritten public offering of 4,119,564 shares of its common stock, and, to certain investors in lieu thereof, pre-funded...
Jul 13, 2020 09:41 pm ET
Altimmune Announces Pricing of a Public Offering of $115 Million of Common Stock and Pre-Funded Warrants
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 3,369,564 shares of its common stock and, to certain investors in lieu thereof,...
Jul 13, 2020 04:01 pm ET
Altimmune Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering and, to certain...
Jul 13, 2020 07:00 am ET
Altimmune and the University of Alabama at Birmingham (UAB) Announce Positive Preclinical Results for Intranasal COVID-19 Vaccine Candidate, AdCOVID™
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from the preclinical studies of its intranasal COVID-19 vaccine candidate, AdCOVID. The studies, which were conducted in collaboration with...
Jul 09, 2020 07:00 am ET
Altimmune Signs Teaming Agreement with DynPort Vaccine Company on U.S. Government Funding Efforts for its COVID-19 Vaccine Candidate, AdCOVID™
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has entered into a teaming agreement with DynPort Vaccine Company (DVC), a General Dynamics Information Technology (GDIT) company, to coordinate U.S....
Jun 30, 2020 07:00 am ET
Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced dosing of the first patient in the Company’s Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. The NasoShield...
Jun 29, 2020 07:00 am ET
Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID™ in Outpatients with Early COVID-19
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it was awarded $4.7 million from the U.S. Army Medical Research & Development Command (USAMRDC) to fund its Phase 1/2 clinical trial of T-COVID, an...
Jun 22, 2020 07:00 am ET
Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell™ Immunotherapeutic for the Treatment of Chronic Hepatitis B
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 2 trial of HepTcell, a...
Jun 03, 2020 09:31 am ET
Thinking about buying stock in Digital Turbine, Mattel, T2 Biosystems, Altimmune, or Moneygram International?
NEW YORK, June 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APPS, MAT, TTOO, ALT, and MGI.
Jun 01, 2020 07:00 am ET
Altimmune Launches Clinical Trial of T-COVIDTM, an Investigational Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has authorized the Company to proceed with a clinical trial of T-COVID, an investigational agent for the...
May 29, 2020 09:31 am ET
Thinking about buying stock in Party City, Altimmune, Trillium Therapeutics, Renren Inc, or Delta Air Lines?
NEW YORK, May 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRTY, ALT, TRIL, RENN, and DAL.
May 27, 2020 09:31 am ET
Thinking about buying stock in Biocept, Celsion Corp, Tilray, Altimmune, or Ford?
NEW YORK, May 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, CLSN, TLRY, ALT, and F.
May 20, 2020 09:31 am ET
Thinking about buying stock in Surface Oncology, Inovio Pharmaceuticals, American Airlines, Altimmune, or Aurora Cannabis?
NEW YORK, May 20, 2020  InvestorsObserver issues critical PriceWatch Alerts for SURF, INO, AAL, ALT, and ACB.
May 14, 2020 11:11 am ET
Thinking about buying stock in AIM ImmunoTech, Wells Fargo, United Airlines, Altimmune, or TOP Ships?
NEW YORK, May 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AIM, WFC, UAL, ALT, and TOPS.
May 13, 2020 05:18 pm ET
Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2020 and provided a business update. “Throughout 2020 we have put significant effort into developing our...
May 12, 2020 07:00 am ET
Altimmune Appoints Former Pfizer and GSK Executive Diane Jorkasky, M.D. to its Board of Directors
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Diane Jorkasky, M.D. to its Board of Directors. With Dr. Jorkasky’s appointment, the size of the board increased to eight members. “We...
May 08, 2020 07:00 am ET
Altimmune to Announce First Quarter 2020 Financial Results on May 14
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first quarter ended March 31, 2020 before the market open and host a conference call on Thursday, May 14, 2020....
Mar 30, 2020 07:00 am ET
Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it is launching a collaboration with the University of Alabama at Birmingham (UAB) on the development of its single-dose, intranasal COVID-19 vaccine,...
Mar 27, 2020 07:15 am ET
Altimmune Announces Financial Results for the Year Ended December 31, 2019 and Provides a Corporate Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December 31, 2019 and provided a corporate update. “2019 was a productive year for the Company with the acquisition of...
Mar 25, 2020 04:30 pm ET
Altimmune to Announce Year End 2019 Financial Results on March 27
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2019 and host a conference call on Friday, March 27, 2020. Conference Call...
Feb 28, 2020 07:00 am ET
Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the advancement of a novel single-dose, intranasal vaccine using Altimmune’s proprietary technology to protect against COVID-19, the disease caused by the...
Feb 19, 2020 04:30 pm ET
Altimmune to Present at the Cowen 40th Annual Health Care Conference
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Vipin K. Garg, Ph.D., President and Chief Executive Officer will present at the Cowen 40th Annual Health Care Conference in Boston on Monday, March 2,...
Feb 04, 2020 07:00 am ET
Altimmune to Present at Upcoming Investor and Scientific Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following conferences during the months of February:   2020 BIO CEO & Investor ConferenceDate:   Monday, February...
Jan 23, 2020 07:00 am ET
Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company today announced that the Company’s immuno-oncology product candidate, ALT-702, met a key pre-clinical efficacy milestone with the demonstration of systemic antitumor activity...
Jan 07, 2020 08:43 am ET
Altimmune to Present at the 2020 NASH-TAG Conference
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an oral presentation at the 2020 NASH-TAG Conference being held on January 9-11, 2020 in Park City, Utah.  Details for the oral presentation are as follows:...
Nov 21, 2019 08:00 am ET
Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on ALT-801, the Company’s GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic...
Nov 13, 2019 04:15 pm ET
Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended September 30, 2019 and provided a business update. “We are pleased with our progress in 2019, as we have...
Nov 06, 2019 07:00 am ET
Altimmune to Announce Third Quarter 2019 Financial Results on November 14
Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it will report financial results for the three and nine months ended September 30,...
Oct 10, 2019 07:00 am ET
Altimmune to Participate in Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will participate in the following investor conferences during the months of October and November:  H.C. Wainwright 3rd Annual NASH Investor...
Sep 09, 2019 07:00 am ET
Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed M. Scott Harris, M.D. as Chief Medical Officer. Dr. Harris is succeeding Dr. Sybil Tasker, who resigned June 30, 2019 to continue her...
Aug 21, 2019 07:00 am ET
Altimmune Announces $3.7 Million in Additional BARDA Funding to Advance NasoShield™ Clinical Development
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Biomedical Advanced Research and Development Authority (BARDA) is modifying its existing anthrax vaccine development contract with Altimmune by...
Aug 13, 2019 04:15 pm ET
Altimmune Announces Second Quarter 2019 Financial Results and Provides a Business Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2019 and provided a business update. "2019 continues to be a transformative year for...
Aug 05, 2019 07:00 am ET
Altimmune to Announce Second Quarter 2019 Financial Results on August 14
Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it will report financial results for the three and six months ended June 30, 2019...
Jul 15, 2019 07:00 am ET
Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc.
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of Spitfire Pharma, Inc., including the product candidate ALT-801, a potent GLP-1/Glucagon receptor...
Jul 09, 2019 07:00 am ET
Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has entered into an agreement to acquire Spitfire Pharma, Inc. (Spitfire) including its product candidate SP-1373 (to be renamed ALT-801), a potent...
Jun 12, 2019 08:00 am ET
Altimmune Appoints Will Brown as Chief Financial Officer
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed Will Brown as Chief Financial Officer. Mr. Brown has been serving as the Acting Chief Financial Officer since May 2018. “Will has proven to...
Jun 10, 2019 08:00 am ET
Altimmune Announces Successful Pre-IND Meeting with FDA
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding its Phase 2 trial...
Jun 05, 2019 08:00 am ET
Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biotechnology company, today announced that it has received additional patent protection for its HepTcell and ALT-702 programs in the United States. “We are pleased to strengthen our intellectual...
May 14, 2019 04:15 pm ET
Altimmune Announces First Quarter 2019 Financial Results and Provides a Business Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the first quarter ended March 31, 2019 and provided a business update. "We made great progress in the first quarter, as we executed...
May 08, 2019 08:00 am ET
Altimmune to Announce First Quarter 2019 Financial Results on May 15
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March 31, 2019 before the market open and host a conference call on Wednesday, May 15,...
Apr 11, 2019 09:27 am ET
Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced an oral presentation at the World Vaccine Congress being held in Washington D.C. on April 14-17, 2019. The presentation will take place on April 16, 2019 at...
Apr 01, 2019 04:20 pm ET
Altimmune Announces Financial Results for the Year Ended December 31, 2018 and Provides Corporate Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the year ended December 31, 2018, and provided a corporate update. "We made great progress in 2018, starting with encouraging...
Mar 21, 2019 04:15 pm ET
Altimmune to Announce Year End 2018 Financial Results on April 2
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the year ended December 31, 2018 before the market open and host a conference call on Tuesday, April 2, 2019....
Mar 19, 2019 09:31 am ET
Thinking about buying stock in Altimmune Inc., Dare Bioscience Inc., Phasebio Pharmaceuticals Inc., Stoneco Ltd., or Tilray Inc.?
NEW YORK, March 19, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALT, DARE, PHAS, STNE, and TLRY.
Mar 19, 2019 07:00 am ET
Altimmune Announces Positive Results from NasoVAX Extension Study
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced additional positive data from a Phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate. Data from this study demonstrated that 100%...
Mar 14, 2019 09:00 am ET
Altimmune to Participate at 31st Annual ROTH Conference
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, announced today that Vipin K. Garg, Ph.D., President and Chief Executive Officer, and Will Brown, Acting Chief Financial Officer, will provide a corporate overview at the...
Mar 12, 2019 01:34 pm ET
Altimmune Announces Closing of $14 Million Registered Direct Offering
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the closing of the previously announced registered direct offering of common units and pre-funded units receiving gross proceeds of $14 million. On March...
Mar 08, 2019 09:29 am ET
Altimmune Announces $14 million Registered Direct Offering
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a purchase agreement with two institutional investors for the purchase of common units and pre-funded units for a combined total of...
Jan 29, 2019 08:00 am ET
Altimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress™ in Vienna, Austria
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced results of its recently completed HepTcell Phase 1 clinical trial will be presented on April 12, 2019 at The International Liver Congress sponsored by The...
Dec 13, 2018 07:01 am ET
Altimmune Announces Clinical Program Updates and Plans for Pipeline Expansion
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced updates to its clinical programs and plans to further expand its pipeline. NasoVAXAs previously announced in September 2018, a monovalent version of...
Nov 30, 2018 06:06 pm ET
Altimmune Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Altimmune, Inc. (NASDAQ: ALT), a clinical-stage immunotherapeutics company, granted equity awards on November 30, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Altimmune’s 2018 Inducement Grant...
Nov 27, 2018 09:00 am ET
Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the appointment of Vipin K. Garg, Ph.D. as its President and Chief Executive Officer succeeding Bill Enright, current President and Chief Executive Officer,...
Nov 13, 2018 04:50 pm ET
Altimmune Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the three and nine months ended September 30, 2018. Recent Corporate Highlights...
Oct 26, 2018 11:29 am ET
Altimmune to Present at Dawson James Securities 4th Annual Small Cap Growth Conference
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer will provide a corporate overview at the Dawson James Securities 4th Annual Small Cap Growth...
Oct 08, 2018 09:00 am ET
Altimmune Announces $25 million Registered Direct Offering
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a purchase agreement with several institutional investors for the purchase of common units and pre-funded units for a combined total of...
Oct 03, 2018 08:00 am ET
Altimmune Closes on $16.9 Million in Funding
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it closed the previously announced underwritten public offering of common units and pre-funded units for gross proceeds of $12 million. Together with the...
Sep 28, 2018 09:01 am ET
Altimmune Announces Pricing of $12 Million Underwritten Public Offering
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the pricing of an underwritten public offering of common units and pre-funded units for a combined total of 2,400,000 units. Each common unit is being sold...
Sep 24, 2018 09:00 am ET
Altimmune Announces $4.9 million Registered Direct Offering of Common Stock
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into purchase agreements with several institutional investors for the purchase in a registered direct offering of 286,633 shares of its...
Sep 24, 2018 08:00 am ET
Altimmune Awarded $2.5 Million in Additional BARDA Funding to Support NasoShield™ Development
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that the Biomedical Advanced Research and Development Authority (BARDA) is modifying its existing contract with Altimmune by adding $2.5 million to the...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.